02159nas a2200313 4500000000100000008004100001653001900042653001700061653001500078653001100093653001300104100001500117700001500132700001500147700001700162700001100179700001300190700001400203700001000217700001200227700001600239700001500255700001300270700001500283700001200298700001200310245007400322520144900396 2025 d10aActinomycetoma10aBurkina Faso10aEumycetoma10aGrains10aMycetoma1 aOuangré A1 aYerbanga I1 aSavadogo I1 aOuédraogo H1 aBado N1 aNagalo A1 aTraoré F1 aDem A1 aBouda S1 aKoulybari D1 aSawadogo A1 aDiallo S1 aGangneux J1 aFahal A1 aBamba S00aBurden of mycetoma in Burkina Faso: case series and systematic review3 a
Mycetoma is a chronic inflammatory disease characterized by progressive and devastating granulomatous subcutaneous tissue involvement. It primarily occurs in regions classified within the ‘mycetoma belt’, encompassing various countries. Notably, West African nations, including Burkina Faso (BF), are situated within this belt, yet there is a significant lack of data regarding mycetoma in these regions. With this background, this study set out to determine the mycetoma prevalence in BF. A comprehensive review was conducted to document the presence of mycetoma in BF. Searches were performed in PubMed, ScienceDirect, African Journals Online (AJOL) and Google Scholar databases. Data were reported following the Preferred Reporting Items for Systematic and Meta-analyses (PRISMA) guidelines. Additionally, the study encompassed a case series involving three patients. From 1960 to 2024, 25 mycetoma cases have been documented in BF. Overall, the clinical cases share similar sociodemographic, clinical, diagnostic, therapeutic and outcome characteristics. Specifically, these cases illustrate that mycetoma predominantly affects vulnerable groups in BF. The majority of mycetoma cases (96%) were reported in the Sahelian zone of BF. Predominantly, these cases (80%) had foot mycetoma. This study highlights the challenges of mycetoma management in BF, indicating significant obstacles in early diagnosis and effective treatment.